As previously reported, Mizuho initiated coverage of Exact Sciences (EXAS) with an Outperform rating and $60 price target The firm is “bullish” given the launch in Q2 of the next-generation flagship Cologuard Plus test with improved sensitivity and specificity, supportive survey results suggesting Cologuard Plus test improvements place it against Colonoscopy as first-line screening, and what it calls an “undervalued profit story.” The firm also cites other 2025 product launches, including the company increasing its cancer diagnostic offerings near-term with Oncodetect for MRD and blood-testing for both CRC and multi-cancer down the line.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences initiated with an Outperform at Mizuho
- Strategic Developments and Product Launch Drive Buy Rating for Exact Sciences
- Exact Sciences announces launch of Cologuard Plus test
- Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion
- Exact Sciences price target lowered to $60 from $73 at Guggenheim